Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 Over a 24-Week Treatment Period

NCT05324293 is registered in ClinicalTrials.gov with Hope Medicine (Nanjing) Co., Ltd as lead sponsor.

NCT NCT05324293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05324293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 Over a 24-Week Treatment Period
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
May 11, 2022
Completion date
September 11, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia